Abstracts tagged "juvenile dermatomyositis"

Abstract Number: 2461 • 2015 ACR/ARHP Annual Meeting
Identification of Target Antigens for Anti-Endothelial Cell Antibodies in Patients with Pediatric Rheumatic Diseases Using Proteomics
Rie Karasawa¹, Mayumi Tamaki¹, Yanmin Chen², Kaiyu Jiang², Kazuo Yudoh¹ and James Jarvis², ¹Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan, ²Pediatrics, The University at Buffalo, Buffalo, NY
Background/Purpose: Juvenile dermatomyositis (JDM), the most common inflammatory myopathy of childhood, is a rare systemic autoimmune vasculopathy. Juvenile idiopathic arthritis (JIA), the most common pediatric…
Abstract Number: 2469 • 2015 ACR/ARHP Annual Meeting
The Lymphocyte Repertoire in Juvenile Dermatomyositis
Lauren A. Henderson¹, Edwin Anderson¹, Robert C. Fuhlbrigge^1,2, Luigi D. Notarangelo^1,3,4 and Susan Kim¹, ¹Division of Immunology, Boston Children's Hospital, Boston, MA, ²Department of Dermatology, Brigham and Women's Hospital, Boston, MA, ³The Manton Center for Orphan Disease Research, Boston Children's Hospital, Boston, MA, ⁴Harvard Stem Cell Institute, Boston, MA
Background/Purpose: In adult dermatomyositis, clonal populations of T lymphocytes with shared variable (V) gene usage have been identified, suggesting aberrant T cell responses to a…
Abstract Number: 2900 • 2014 ACR/ARHP Annual Meeting
Clinically Inactive Disease in Juvenile Dermatomyositis – a Proposed Revision to the Pediatric Rheumatology International Trials Organisation Criteria
Beverley Almeida¹, Raquel Campanilho-Marques², Katie Arnold², Lucy R. Wedderburn^3,4, Clarissa A Pilkington⁵ and Kiran Nistala⁶, ¹Department of Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ²Infection, Inflammation and Rheumatology Section, UCL Institute for Child Health, London, United Kingdom, ³Institute of Child Health, University College London, London, United Kingdom, ⁴Arthritis Research UK Centre for Adolescent Rheumatology,, UCL, UCLH, GOSH NHS Trust, London, United Kingdom, ⁵Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ⁶Centre for Rheumatology, University College London, London, United Kingdom
Background/Purpose: Juvenile dermatomyositis (JDM) affects 3 children/million/year with myositis and skin disease being the typical features. The Pediatric Rheumatology International Trials Organisation (PRINTO) have recently…
Abstract Number: 2211 • 2014 ACR/ARHP Annual Meeting
Epidemiologic and Clinical Features of Patients with Adult and Juvenile Dermatomyositis, Polymyositis and Inclusion Body Myositis from Myovision, a National Myositis Patient Registry
Abdullah Faiq¹, Payam Noroozi Farhadi¹, Nastaran Bayat¹, Mikaela Chase¹, Anna Jansen¹, Karen Malley², Jesse Wilkerson³, Kathryn Rose⁴, Caroll Co⁴, Lukasz Itert⁵, Anne Johnson⁶, Richard Morris⁴, Christine Parks⁷, Edward H. Giannini⁸, Hermine I. Brunner⁸, Frederick W. Miller¹, Bob Goldberg⁹ and Lisa G. Rider¹, ¹Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ²Malley Research Programming, Inc, Bethesda, MD, ³Social and Scientific Systems, Inc., Research Triangle Park, NC, ⁴Social and Scientific Systems, Inc., Durham, NC, ⁵Division of Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁷Epidemiology Branch, NIEHS, NIH, Research Triangle Park, NC, ⁸Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹The Myositis Association, Alexandria, VA
Background/Purpose: The myositis syndromes are rare systemic autoimmune diseases, little is known about their epidemiology. We describe the demographics and comorbidities of patients in a…
Abstract Number: 2222 • 2014 ACR/ARHP Annual Meeting
Predictors of Myositis Treatments Received and Associated Treatment Responses in Myovision, a National Myositis Patient Registry
Abdullah Faiq¹, Payam Noroozi Farhadi¹, Jesse Wilkerson², Nastaran Bayat¹, Anna Jansen³, Kathryn Rose⁴, Lukasz Itert⁵, Anne Johnson⁶, Christine Parks⁷, Edward H. Giannini⁸, Hermine I. Brunner⁹, Bob Goldberg¹⁰, Richard Morris⁴, Frederick W. Miller¹ and Lisa G. Rider¹, ¹Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ²Social and Scientific Systems, Inc., Research Triangle Park, NC, ³Environmental Autoimmunity Group, NIEHS / EAG, Bethesda, MD, ⁴Social and Scientific Systems, Inc., Durham, NC, ⁵Division of Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁷Epidemiology Branch, NIEHS, NIH, Research Triangle Park, NC, ⁸Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹PRCSG, Cincinnati, OH, ¹⁰The Myositis Association, Alexandria, VA
Background/Purpose: Little is known about medications received for myositis and patients’ responses to therapies. We present information on self-reported myositis therapy use and responses from…
Abstract Number: 1317 • 2014 ACR/ARHP Annual Meeting
Anti-p155/140 Autoantibodies and Selected Features at Illness Onset Are Associated with a Chronic Course of Illness in the Juvenile Idiopathic Inflammatory Myopathies
G. Esther A. Habers¹, Adam M. Huber², Gulnara Mamyrova³, Ira Targoff⁴, Chantal Boonacker⁵, Marco van Brussel¹, Frederick W. Miller⁶, Lisa G. Rider⁶ and Annet van Royen-Kerkhof⁷, ¹Child Development and Exercise Center, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, Netherlands, ²IWK Health Centre, Halifax, NS, Canada, ³Rheumatology, George Washington University, Washington, DC, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands, ⁶Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ⁷Paediatric Immunology and Rheumatology, University Medical Centre Utrecht - Wilhelmina Children's Hospital, Utrecht, Netherlands
Background/Purpose : Three types of disease courses can be distinguished in patients with juvenile idiopathic inflammatory myopathies (JIIM), namely monocyclic (M), polycyclic (P), and chronic…
Abstract Number: 1981 • 2013 ACR/ARHP Annual Meeting
Developing International Consensus Definitions Of Improvement For Adult and Juvenile Dermatomyositis and Polymyositis
Saad Feroz¹, Nicolino. Ruperto², Jiri Vencovsky³, Peter A. Lachenbruch¹, Brian Erman⁴, Adam Huber⁵, Brian M. Feldman⁶, Ingrid E. Lundberg⁷, Angela Pistorio⁸, Howard Rockette⁹, Frederick W. Miller¹, Rohit Aggarwal¹⁰, Lisa G. Rider¹, for The ACR-EULAR Myositis Response Criteria Project Group¹¹, Angelo Ravelli¹², Clarissa Pilkington¹³ and Sheila K. Oliveira¹⁴, ¹Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ²PRINTO, IRCCS G. Gaslini, Genoa, Italy, ³Institute of Rheumatology, Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴SRA International, Research Triangle Park, NC, ⁵IWK Health Centre, Halifax, NS, Canada, ⁶Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, ⁷Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ⁸PRINTO, Genoa, Italy, ⁹University of Pittsburgh, Pittsburgh, PA, ¹⁰Medicine / Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹¹NIEHS, NIH, Bethesda, MD, ¹²Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy, ¹³Rheumatology Department, Great Ormond Street Hospital, London, United Kingdom, ¹⁴Pediatric Rheumatology, Instituto de Pediatria e Puericultura Martagão Gesteira (IPPMG) da Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
Background/Purpose: IMACS and PRINTO have developed preliminary core set activity measures and definitions of improvement (DOIs). However, these were developed from small and partially retrospective…
Abstract Number: 2473 • 2012 ACR/ARHP Annual Meeting
A Randomized Trial in New Onset Juvenile Dermatomyositis: Prednisone Versus Prednisone Plus Cyclosporine Versus Prednisone Plus Methotrexate
Nicolino Ruperto¹, Angela Pistorio², Sheila Oliveira³, Rubén J. Cuttica⁴, Angelo Ravelli¹, Michel Fischbach⁵, Stefan Hagelberg¹, Tadej Avcin⁶, Emanuel Cheuret¹, Fabrizia Corona⁷, Gerard Couillault¹, Frank Dressler¹, Valeria Gerloni¹, Gary Sterba Sr.¹, Francesco Zulian¹, Maria Teresa Apaz¹, Adriana Cespedes-Cruz¹, Rolando Cimaz¹, Fabrizio De Benedetti⁸, Pierre Quartier¹, Ricardo Russo¹, Nico Wulffraat¹, Simona Angioloni¹ and Alberto Martini⁹, ¹Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy, ²PRINTO, Genoa, Italy, ³Istituto Giannina Gaslini, Pediatria II, Reumatologia, Paediatric Rheumatology International Trials Organisation (PRINTO) Coordinating Center, Genoa, Italy, Genova, Italy, ⁴Hospital de Niños Pedro de Elizalde - University of Buenos Aires, Buenes Aires, Argentina, ⁵Pediatric Rheumatology International Trials Organization (PRINTO)-Istituto Gaslini, Genova, Italy, ⁶The Ljubljana University Medical Centre, Pediatric Clinic, Ljubljana, Slovenia, ⁷Reumatologia Pediatrica, Paediatric Department University of Milano, Milano, Italy, ⁸IRCCS Ospedale Pediatrico Bambino Gesú, Rome, Italy, ⁹Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH
Background/Purpose: Data regarding the safety and efficacy of treatment regimens for juvenile dermatomyositis(JDM) tends to be from anecdotal, small, uncontrolled, non-randomized case series. This randomized…
Abstract Number: 1935 • 2012 ACR/ARHP Annual Meeting
Longitudinal Peripheral Blood Lymphocyte Subsets Correlate with Decreased Disease Activity in Juvenile Dermatomyositis
Floranne C. Ernste¹, Cynthia S. Crowson², Consuelo Lopez de Padilla³, Molly Hein⁴, Abigail B. Green² and Ann M. Reed⁵, ¹Division of Rheumatology, Mayo Clinic Rochester, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ³Rheumatology/Immunology Research, Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Rochester, MN, ⁵Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Perturbations in peripheral blood lymphocyte (PBL) subsets in juvenile dermatomyositis (JDM) are variably and inconsistently reported in active and inactive disease. Decreased PBL CD8+…
Abstract Number: 1037 • 2012 ACR/ARHP Annual Meeting
Magnetic Resonance Imaging (MRI) Assessment of Inflammatory Myopathy: Quantitative Fat-Corrected Muscle T2 and Conventional T2 Measurement Versus Standard MRI and Clinical Metrics
Lawrence Yao¹, Adrienne L. Yip², Sepehr Mesdaghinia², Ashkan Shademan², Joseph A. Shrader³, Anna V. Jansen⁴, Frederick W. Miller⁴ and Lisa G. Rider⁴, ¹Diagnostic Radiology, NIH Clinical Center, Bethesda, MD, ²NIEHS, NIH, Bethesda, MD, ³Rehabilitation Medicine, Clinical Center, NIH, Bethesda, MD, ⁴Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD
Background/Purpose: Active muscle disease in patients with idiopathic inflammatory myopathies (IIM) is characterized by prolonged muscle T2 relaxation on MRI. We examined the utility of…
Abstract Number: 291 • 2012 ACR/ARHP Annual Meeting
Illness Features Associated with an Increased Risk of Mortality in Children with Juvenile Idiopathic Inflammatory Myopathies
Adam M. Huber¹, Gulnara Mamyrova², Julia A. Lee³, Peter A. Lachenbruch⁴, Ira N. Targoff⁵, Frederick W. Miller⁴, Lisa G. Rider⁴ and Childhood Myositis Heterogeneity Study Group⁶, ¹Dalhousie University, Halifax, NS, Canada, ²Rheumatology, George Washington University, Washington, DC, ³Environmental Autoimmunity Grp, NIEHS, Bethesda, MD, ⁴Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ⁵Arthritis and Immunology, Oklahoma Medical Research Foun, Oklahoma City, OK, ⁶Bethesda, MD
Background/Purpose: Juvenile idiopathic inflammatory myopathies (JIIM) are potentially life-threatening systemic autoimmune diseases but little in known regarding factors associated with mortality. Methods: Patients enrolled in…
Abstract Number: 207 • 2012 ACR/ARHP Annual Meeting
Interferon-Driven Chemokines Are Associated with Changes in Disease Activity Among Rituximab-Treated Refractory Myositis Patients with Pulmonary Involvement – the RIM Study
Cynthia S. Crowson¹, Ann M. Reed², Molly Hein³, Abigail B. Green¹, Consuelo Lopez de Padilla⁴, Rohit Aggarwal⁵, Dana P. Ascherman⁶, Marc C. Levesque⁷ and Chester V. Oddis⁸, ¹Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ²Rheumatology, Mayo Clinic, Rochester, MN, ³Mayo Clinic, Rochester, MN, ⁴Rheumatology/Immunology Research, Mayo Clinic, Rochester, MN, ⁵Medicine, University of Pittsburgh, Pittsburgh, PA, ⁶Medicine/Rheumatology, University of Miami, Miami, FL, ⁷Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁸Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The Rituximab in Myositis (RIM) Study provides a unique resource for biomarker investigation of homogeneously treated refractory adult and juvenile myositis patients. Building on…
Abstract Number: 206 • 2012 ACR/ARHP Annual Meeting
Clinical, Laboratory, and Cellular Responses in the Rituximab in Myositis Trial in Patients Enrolled At the National Institutes of Health
Lisa G. Rider¹, Adrienne L. Yip², Iren Horkayne-Szakaly³, Rita Volochayev², Joseph A. Shrader⁴, Maria L. Turner⁵, Heidi H. Kong⁵, Minal S. Jain⁴, Anna V. Jansen¹, Chester V. Oddis⁶, Thomas A. Fleisher⁷ and Frederick W. Miller¹, ¹Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ²National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ³Joint Pathology Center, Silver Spring, MD, ⁴Rehabilitation Medicine, Rehab Medicine, NIH Clinical Center, Bethesda, MD, ⁵Dermatology Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD, ⁶Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁷Laboratory Medicine, Laboratory Medicine, NIH Clinical Center, Bethesda, MD
Background/Purpose: To assess changes in myositis core set measures, clinical and laboratory data, and paired muscle biopsies from NIH patients enrolled in the Rituximab in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].